Orca Bio received landmark FDA approval for Tregzi, described as the first cell therapy based on regulatory T cells (Tregs). The company said clinical trial results showed a reduced risk of graft-versus-host disease, a common complication associated with allogeneic stem cell transplants for blood cancers. Regulatory T-cell therapies represent a distinct strategy from conventional immunosuppression by targeting immune regulation rather than broad immune suppression. The FDA nod places Treg-based therapy into a real-world post-market setting. The approval also broadens the commercial and operational focus for cell therapy developers, with transplant centers likely to become the primary execution sites for adoption and outcomes tracking.